Literature DB >> 33757968

Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.

Brian J Boyarsky1, Jake A Ruddy1, Caoilfhionn M Connolly2, Michael T Ou1, William A Werbel3, Jacqueline M Garonzik-Wang1, Dorry L Segev4,5, Julie J Paik2.   

Abstract

Entities:  

Keywords:  COVID-19; antirheumatic agents; autoimmune diseases; vaccination

Mesh：

Substances：

Year:  2021        PMID： 33757968      PMCID： PMC8822300          DOI： 10.1136/annrheumdis-2021-220289

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   27.973


× No keyword cloud information.
  56 in total

1.  Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios.

Authors:  Ernesto Cairoli; Gerard Espinosa
Journal:  Med Clin (Engl Ed)       Date:  2021-08-07

Review 2.  Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third dose.

Authors:  Andrew N Margioris
Journal:  Hormones (Athens)       Date:  2022-06-24       Impact factor: 3.419

3.  High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.

Authors:  Jake A Ruddy; Caoilfhionn Marie Connolly; Brian J Boyarsky; William A Werbel; Lisa Christopher-Stine; Jacqueline Garonzik-Wang; Dorry L Segev; Julie J Paik
Journal:  Ann Rheum Dis       Date:  2021-05-24       Impact factor: 19.103

4.  Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019.

Authors:  Ghady Haidar; John W Mellors
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

5.  SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.

Authors:  Daniel Mrak; Selma Tobudic; Maximilian Koblischke; Marianne Graninger; Helga Radner; Daniela Sieghart; Philipp Hofer; Thomas Perkmann; Helmuth Haslacher; Renate Thalhammer; Stefan Winkler; Stephan Blüml; Karin Stiasny; Judith H Aberle; Josef S Smolen; Leonhard X Heinz; Daniel Aletaha; Michael Bonelli
Journal:  Ann Rheum Dis       Date:  2021-07-20       Impact factor: 19.103

Review 6.  Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).

Authors:  Cara D Varley; Kevin L Winthrop
Journal:  Curr Rheumatol Rep       Date:  2021-07-16       Impact factor: 4.592

7.  Impact of methotrexate on first-dose COVID-19 mRNA vaccination.

Authors:  Caoilfhionn M Connolly; Julie J Paik
Journal:  Lancet Rheumatol       Date:  2021-07-08

8.  Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease.

Authors:  John A Mackintosh; Marc Lipman; David M Lowe; Elisabetta A Renzoni
Journal:  Lancet Respir Med       Date:  2021-07-15       Impact factor: 30.700

Review 9.  COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.

Authors:  Jason D Goldman; Philip C Robinson; Thomas S Uldrick; Per Ljungman
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

10.  Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.

Authors:  Yolanda Braun-Moscovici; Marielle Kaplan; Maya Braun; Doron Markovits; Samy Giryes; Kohava Toledano; Yonit Tavor; Katya Dolnikov; Alexandra Balbir-Gurman
Journal:  Ann Rheum Dis       Date:  2021-06-18       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.